| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d6659b9f88f4eb2c7adc8137591282bc |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-22 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-22 |
| filingDate |
2015-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_acab65d924272b9829dd81093b904e4c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f7796701285d3fa910aa25b61370592
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_95d9e12b91853b61565d6405cac3c4dc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_87692b122e2445b982ffa2213832d9ef |
| publicationDate |
2016-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2016006034-A |
| titleOfInvention |
Monoclonal antibodies against basic fibroblast growth factor |
| abstract |
The present invention provides a neutralizing monoclonal antibody against basic fibroblast growth factor (FGF2), a pharmaceutical composition comprising said antibody, and a therapeutic method comprising administering such a pharmaceutical composition to a patient. A monoclonal antibody (mAb) that binds to and neutralizes FGF2 and is genetically engineered mAb. A typical antibody is GAL-F2 and its chimeric and humanized forms, and mAbs that have the same epitope as GAL-F2 or compete for binding with GAL-F2. A cell line producing such an antibody. A pharmaceutical composition comprising a neutralizing anti-FGF2 antibody (eg, chimeric or humanized GAL-F2). A pharmaceutical composition administered to a patient to treat cancer or other diseases. [Selection figure] None |
| priorityDate |
2008-05-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |